Carrie Nagorka, Senior Editor

Arcutis Biotherapeutics announced new positive data involving itch and itch-related sleep loss in adults with plaque psoriasis.

As the Society of Dermatology Physician Assistants Conference begins this week, speakers share what they’re excited about.

Robert Kirsner, MD, PhD, discusses how to heal difficult wounds at the 2022 SDPA Fall Conference.

Hilary Baldwin, MD, discusses the pathology and treatment options for acne and rosacea at the SDPA 2022 Fall Conference.

At the 2022 SDPA Conference, Cynthia Trickett, PA-C, MPAS talks about her 2 sessions; psoriasis primer and kodachromes.

Renata Block, MMS, PA-C., explains the importance of The Society of Dermatology Physician Assistants (SDPA) 2022 Conference.

Matthew Zirwas, MD, FAAD, associate professor of dermatology at Ohio University in Athens, Ohio provides updates on treatment options for AD at the 2022 SDPA Fall Conference.

At the 2022 SDPA Conference, Ted Rosen, MD, discusses skin conditions that could often be mistaken for vitiligo.

At the 2022 SDPA Conference, Ted Rosen, MD, discusses mundane and rare diseases that often present as vitiligo.

As the Society of Dermatology Physician Assistants Conference continues, its president discussed what she hopes attendees take away from the event.

A speaker discusses her sessions on the latest in cosmetic dermatology at the 2022 SPDA Fall Conference.

Ilanit Samuels, MCMS, Pa-C, provides an in-depth explanation of how cosmetic lasers work and how they play a role in cosmetic dermatology at the 2022 SDPA Conference.

The 20th annual SDPA Conference begins Thursday, November 17th in Miami, Florida, and continues through Sunday, November 20th.

In this episode, Bernard Cohen, MD, professor of pediatrics and dermatology at Johns Hopkins University School of Medicine, talks about how physicians and patients should treat atopic dermatitis in the winter months, and some new data on treating newborns.

A real-world, cohort study finds popular skin rash drugs also boost moods.

Dry shampoo products were found to contain elevated levels of a cancer-causing chemical.

Data demonstrates an increase in the proportion of patients achieving regimentation with longer duration of ruxolitinib cream treatment.

Acute exposure can elevate biomarkers associated with contact dermatitis and psoriasis.

Patients with DM may find relief from a psoriasis drug in addition to their regular therapies.

In this episode, Jeffrey M. Cohen, MD, a board-certified medical dermatologist and the director of the Psoriasis Treatment Program at the Yale School of Medicine, discusses treatment options for adolescents with atopic dermatitis, how the changing seasons can affect flare-ups, and what caregivers can do at home to help prevent extreme itching.

A new study shows the AD drug does not interfere with vaccinations or increase severity.

Patients saw improvements in the first-ever phase 3 trial of the blood therapy for the condition.

Peter Lio, MD, talks about the difficulties and strategies used when treating patients with this common skin disorder.

NEXGEL’s dressing demonstrates significant scar improvement as early as 6 weeks after surgery.

Two expert dermatologists discuss the relationship between PsA and PsO in this DermView series recap.

New research finds psoriasis drug apremilast could help patients lose weight.

Sanofi and Regeneron’s dupliumab will provide relief to patients with extreme itch and skin lesions.

Recent study results demonstrated a noticeable reduction in itch just 12 hours after application of ruxolitinib.

The CHMP's recommendations are based on data from a phase 3 ECZTRA 6 trial in adolescents with moderate-to-severe AD cases.

Aerolase launches the Exci308 to help fight common skin conditions.